SEC Comment Letter for Fusion Pharmaceuticals Inc. (CIK 0001805890) — Jun 23, 2023
Fusion Pharmaceuticals Inc. (CIK 0001805890)
Date: June 23, 2023 · CIK: 0001805890 · Accession: 0000000000-23-006734
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272713
Letter
United States securities and exchange commission logo June 23, 2023 Maria Stahl Chief Legal Officer Fusion Pharmaceuticals Inc. 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 Re:Fusion Pharmaceuticals Inc. Registration Statement on Form S-3 Filed June 16, 2023 File No. 333-272713 Dear Maria Stahl: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William A. Magioncalda, Esq.
Show Raw Text
United States securities and exchange commission logo
June 23, 2023
Maria Stahl
Chief Legal Officer
Fusion Pharmaceuticals Inc.
270 Longwood Road South
Hamilton, Ontario, Canada, L8P 0A6
Re:Fusion Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed June 16, 2023
File No. 333-272713
Dear Maria Stahl:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: William A. Magioncalda, Esq.